Hims & Hers Health, Inc. (HIMS)
Where Does Hims & Hers Stock Go From Here?
Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright?
2 Incredibly Cheap Growth Stocks to Buy Right Now
Look beyond the stock price at the business when shares are volatile.
2 No-Brainer Growth Stocks to Buy With $500 Right Now
Consistently investing even moderate sums can grow your portfolio with time.
Hims & Hers Health (HIMS) Soars 10.1%: Is Further Upside Left in the Stock?
Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Hims & Hers Stock Joins S&P 600: Is More Upside on the Horizon?
The healthcare sector is usually regarded as one of the safest and most stable spaces in the market, which becomes especially important and attractive during volatile periods such as today in the S&P 500 index. However, there is still a preference for the technology sector, and this preference is now being diversified away from the semiconductor industry and into other niches.
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly's weight-loss drug shortage is over
Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.S. Food and Drug Administration (FDA) that competitor Eli Lilly's obesity and diabetes drugs are no longer facing supply constraints, and have been removed from the shortage list.
Massive News for Hims & Hers Stock: The Truth About Today's Move
Hims & Hers may not be hurt by GLP-1 news the way investors think.
2 Winning Growth Stocks That Are Screaming Buys Right Now
These top stocks are on a winning streak and have the businesses to keep it going.
Hims & Hers Health Stock Falls as FDA Drops Eli Lilly Weight-Loss Drugs From Shortage List
Shares of Hims & Hers Health (HIMS) sank Thursday after the Food and Drug Administration (FDA) said Eli Lilly's (LLY) popular weight-loss treatments, Mounjaro and Zepbound, were no longer on its list of drugs in short supply.
Is the soaring Hims & Hers stock a good investment?
Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in the last 12 months and by 112% this year, outperforming the benchmark Nasdaq 100 and S&P 500 indices and other companies in the healthcare industry.
